Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%

160/4.5 mcg BDF single inhaler therapy vs current best practice

Fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).

1 finding from 1 review

Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes only
OR 1.95 [0.53, 7.21]
8 studies · 8841 participants
Low

160/4.5 mcg BDF single inhaler therapy vs current best practice

Non‐fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).

1 finding from 1 review

Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes only
OR 1.2 [0.9, 1.6]
8 studies · 8841 participants
Low

160/4.5 mcg BDF single inhaler therapy vs current best practice

Withdrawals due to adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).

1 finding from 1 review

Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes only
OR 2.85 [1.89, 4.3]
7 studies · 8411 participants
Moderate